Received 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
|
|
- Vivien Murphy
- 5 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p Vol. 45, No /07/$ doi: /jcm Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods M. A. Pfaller, 1,2 * S. A. Messer, 1 L. Boyken, 1 C. Rice, 1 S. Tendolkar, 1 R. J. Hollis, 1 and D. J. Diekema 1,3 Departments of Pathology 1 and Medicine, 3 Roy J. and Lucille A. Carver College of Medicine, and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa Received 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006 Clinical laboratories frequently face the problem of delayed availability of commercially prepared approved reagents for performing susceptibility testing of new antimicrobials. Although this problem is encountered more often with antibacterial agents, it is also an issue with antifungal agents. A current example is voriconazole, a new triazole antifungal with an expanded spectrum and potency against Candida spp., Aspergillus spp., and other opportunistic fungal pathogens. The present study addresses the use of fluconazole as a surrogate marker to predict the susceptibility of Candida spp. to voriconazole. Reference broth microdilution MIC results for 13,338 strains of Candida spp. isolated from more than 200 medical centers worldwide were used. Voriconazole MICs and interpretive categories (susceptible, <1 g/ml; susceptible dose dependent, 2 g/ml; resistant, >4 g/ml) were compared with those of fluconazole by regression statistics and error rate bounding analyses. For all 13,338 isolates, the absolute categorical agreement was 91.6% (false susceptible or very major error [VME], 0.0%). Since voriconazole is 16- to 32-fold more potent than fluconazole, the performance of fluconazole as a surrogate marker for voriconazole susceptibility was improved by designating those isolates with fluconazole MICs of <32 g/ml as being susceptible to voriconazole, resulting in a categorical agreement of 97% with 0.1% VME. Clinical laboratories performing antifungal susceptibility testing of fluconazole against Candida spp. can reliably use these results as surrogate markers until commercial FDA-approved voriconazole susceptibility tests become available. Downloaded from Voriconazole is a new triazole antifungal agent with broadspectrum activity against Candida spp., Cryptococcus neoformans, Aspergillus spp., and other opportunistic fungal pathogens (2, 9, 12, 21, 22, 25, 27). The in vitro activity of voriconazole against Candida spp. has been documented by broth dilution, agar disk diffusion, and Etest methods (24, 25, 27, 28, 30), and most recently clinically relevant interpretive breakpoints for MIC and disk diffusion testing of Candida spp. have been established by the Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS) (30). The U.S. Food and Drug Administration (FDA) has approved voriconazole for treatment of invasive candidiasis (including candidemia) in nonneutropenic patients (6, 12). Voriconazole has also been FDA approved for treatment of esophageal candidiasis, invasive aspergillosis, and serious infections caused by Fusarium spp. and by Scedosporium apiospermum in patients who are intolerant or refractory to other antifungal agents (9, 19, 21, 22). Similar indications for the use of voriconazole have been approved in Europe, including the use of this agent for the treatment of fluconazole-resistant serious invasive Candida infections (6, 12). * Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA Phone: (319) Fax: (319) michael-pfaller@uiowa.edu. Published ahead of print on 1 November Voriconazole has been shown to be efficacious in both primary (12) and salvage (19, 22) therapy of invasive candidiasis. However, several investigators have recently urged caution regarding its use in heavily azole-exposed patients due to the potential for cross-resistance, especially with fluconazole-resistant strains of Candida glabrata (1, 6, 8, 13, 20). Previously, we have shown that in vitro cross-resistance between fluconazole and voriconazole does exist among clinical isolates of Candida spp. (25, 27, 30). The clinical relevance of this cross-resistance has been documented in case series from three different institutions (1, 13, 20), where clinically significant microbial resistance to voriconazole has been reported among immunocompromised patients (e.g., intensive care and stem cell transplant patients) with a high level of azole (i.e., fluconazole before voriconazole) exposure. Although most of the resistant isolates in these series were C. glabrata, a number of C. albicans, C. tropicalis, and C. parapsilosis isolates were also found to have reduced susceptibility or resistance to both fluconazole and voriconazole (1, 13, 20). Thus, decreased susceptibility to fluconazole may precede, or even predict, decreased susceptibility to voriconazole, and diligent monitoring of candidal infections in highly compromised patients must be continued despite voriconazole coverage, particularly when voriconazole use is preceded by prolonged fluconazole exposure (1, 13, 20). These concerns have led Magill et al. (13) to institute reflexive fluconazole susceptibility testing of patients initial blood isolates as a means of on October 30, 2018 by guest 70
2 VOL. 45, 2007 SUSCEPTIBILITY TESTING OF VORICONAZOLE 71 Downloaded from FIG. 1. Scattergram comparing fluconazole and voriconazole MICs for 13,338 strains of Candida spp. An excellent correlation was observed (r 0.93; y x). The horizontal and vertical lines designate the respective breakpoints for fluconazole and voriconazole. (Adapted from reference 30.) identifying those that may not respond optimally to either fluconazole or voriconazole therapy. Despite the fact that interpretive breakpoints for voriconazole and Candida have been established by CLSI (30), the manufacture of commercially available antifungal susceptibility test systems that incorporate voriconazole is still under development, and none are FDA approved (3, 24). Currently, the Sensititre YeastOne colorimetric antifungal plate (TREK Diagnostic Systems, Cleveland, OH) is FDA approved for testing Candida spp. against fluconazole, itraconazole, and flucytosine (3). Previously, we have shown that fluconazole may serve as a surrogate marker for evaluating the susceptibility of Candida spp. to ravuconazole, an investigative triazole (29). This same approach should be applicable to voriconazole, allowing laboratories to use an FDAapproved commercial MIC panel containing fluconazole to predict the susceptibility of Candida isolates to voriconazole as a temporary measure until FDA approval for voriconazole testing has been granted. In the present study we utilized a large database of susceptibility test results for fluconazole and voriconazole, all determined by CLSI broth microdilution (BMD) methods, to first provide a very robust analysis of cross-resistance between the two agents and additionally to examine the usefulness of fluconazole as a surrogate marker for evaluating voriconazole susceptibility and resistance among Candida spp. MATERIALS AND METHODS Organisms. A total of 13,338 clinical isolates of Candida spp. obtained from more than 200 medical centers worldwide were tested (23). The collection included the following species and numbers of isolates: 7,725 isolates of C. albicans, 1,966 isolates of C. glabrata, 1,623 isolates of C. parapsilosis, 1,253 isolates of C. tropicalis, 312 isolates of C. krusei, 134 isolates of C. lusitaniae, 103 isolates of C. dubliniensis, 92 isolates of C. guilliermondii, 34 isolates of C. pelliculosa, 33 isolates of C. kefyr, 19 isolates of C. famata, 19 isolates of C. rugosa, 7 isolates of C. lipolytica, 5 isolates of C. zeylanoides, 3 isolates of C. inconspicua, 2 isolates of C. lambica, 2 isolates of C. sake, 1 isolate of C. norvegensis, and 5 isolates of Candida spp. not otherwise identified. All were incident isolates from individual patients and were obtained from blood or other normally sterile body fluids (23, 25 27). Isolates were identified by using Vitek and API yeast identification systems (biomerieux, Inc, Hazelwood, MO) supplemented by conventional methods as needed (7). The C. dubliniensis isolates were from mucosal infections and were identified by specific probe hybridization (10). Isolates were stored as water suspensions until used. Prior to testing, each isolate was passaged at least twice on potato dextrose agar (Remel, Lenexa, KS) and CHROMagar (Hardy Laboratories, Santa Maria, CA) to ensure purity and viability. on October 30, 2018 by guest
3 72 PFALLER ET AL. J. CLIN. MICROBIOL. TABLE 1. Fluconazole and voriconazole MIC distribution profiles for 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods a Species (no. of isolates tested) Antifungal agent No. of isolates at MIC ( g/ml) of: C. albicans (7,725) Fluconazole 2,121 4, Voriconazole 5,624 1, C. glabrata (1,966) Fluconazole Voriconazole C. parapsilosis (1,623) Fluconazole Voriconazole C. tropicalis (1,253) Fluconazole Voriconazole C. krusei (312) Fluconazole Voriconazole C. lusitaniae (134) Fluconazole Voriconazole C. dubliniensis (103) Fluconazole Voriconazole C. guilliermondii (92) Fluconazole Voriconazole C. pelliculosa (34) Fluconazole Voriconazole C. kefyr (33) Fluconazole Voriconazole C. famata (19) Fluconazole Voriconazole C. rugosa (19) Fluconazole Voriconazole Candida spp. b (25) Fluconazole Voriconazole Total (13,338) Fluconazole 2,203 4,896 1,849 1, Voriconazole 6,174 2,300 1,232 1, a Broth microdilution MICs determined in accordance with CLSI M27-A2. b Includes C. lipolytica (7 isolates), C. zeylanoides (5 isolates), C. inconspicua (3 isolates), C. lambica (2 isolates), C. sake (2 isolates), C. norvegensis (1 isolate), and Candida spp. not otherwise identified (5 isolates). Susceptibility testing. Reference antifungal susceptibility testing of all isolates was performed by BMD as described by the CLSI (15). Reference powders of fluconazole and voriconazole were obtained from Pfizer Inc. (Groton, CT). MIC interpretive criteria for fluconazole were those published by Rex et al. (32, 33) and recently confirmed by Pfaller et al. (31). Breakpoints were as follows: susceptible (S), 8 g/ml; susceptible dose dependent (SDD), 16 to 32 g/ml; and resistant (R), 64 g/ml. The interpretive breakpoints for voriconazole were those proposed by the CLSI and published by Pfaller et al. (30): S, 1 g/ml; SDD, 2 g/ml; and R, 4 g/ml. Analysis of results. All MIC results (in g/ml) for fluconazole were directly compared with those for voriconazole by regression statistics and by scattergram (Fig. 1). The error rate bounding method to minimize intermethod interpretive error was also applied using the interpretive breakpoints described above. Acceptable error limits used in this comparison were those cited by the CLSI (8) and by other authors (4, 11). The definitions of errors used in this analysis were as follows: a very major error (VME), or a false-susceptible error, was an S result for the surrogate marker fluconazole and an R result for voriconazole; a major error (ME), or a false-resistant error, was an R result for fluconazole and an S result for voriconazole; and minor errors occurred when the result for one of the agents was S or R and that for the other agent was SDD. In general, for an agent to be considered a reliable surrogate, the VME rate should be 1.5% of all results, and the absolute categorical agreement between methods should be 90% (4, 11, 14). RESULTS AND DISCUSSION Table 1 depicts the MIC distribution profiles for fluconazole and voriconazole determined for 13,338 strains of Candida spp. by using CLSI (15)-validated BMD methods. Overall, 12,087 isolates (90.6%) were S, 855 (6.4%) were SDD, and 396 (3.0%) were categorized as R to fluconazole. Conversely, 13,115 (98.3%) were S, 110 (0.8%) were SDD, and 113 (0.9%) were R to voriconazole at MIC breakpoints of 1 g/ml, 2 g/ml, and 4 g/ml, respectively. The modal MIC for voriconazole was g/ml, compared to 0.25 g/ml for fluconazole. De-
4 VOL. 45, 2007 SUSCEPTIBILITY TESTING OF VORICONAZOLE 73 TABLE 2. Use of fluconazole to predict susceptibility patterns of voriconazole, using 13,338 clinical isolates of Candida spp. from the Global Antifungal Surveillance Program TABLE 3. Absolute categorical agreement and error rates when the azole surrogate fluconazole result was used to predict voriconazole susceptibility of Candida spp. Species (no. of isolates tested) Fluconazole susceptibility category a No. (%) in voriconazole category b : S ( 1 g/ml) SDD (2 g/ml) R ( 4 g/ml) Organism(s) tested No. of isolates % a : Agreement VME ME Minor errors All Candida (13,338) S 12,087 (90.6) 0 (0.0) 0 (0.0) SDD 836 (6.3) 16 (0.1) 3 (0.1) R 192 (1.4) 94 (0.7) 110 (0.8) All Candida minus C. krusei (13,026) S 12,078 (92.7) 0 (0.0) 0 (0.0) SDD 659 (5.1) 16 (0.1) 3 (0.1) R 68 (0.5) 93 (0.7) 109 (0.8) C. albicans (7,725) S 7,638 (98.9) 0. (0.0) 0 (0.0) SDD 37 (0.5) 1 (0.01) 0 (0.0) R 25 (0.3) 9 (0.1) 15 (0.19) C. glabrata (1,966) S 1,217 (61.9) 0 (0.0) 0 (0.0) SDD 557 (28.3) 10 (0.5) 1 (0.1) R 30 (1.5) 79 (4.0) 72 (3.7) C. parapsilosis (1,623) S 1,577 (97.2) 0. (0.0) 0 (0.0) SDD 36 (2.2) 2 (0.1) 0 (0.0) R 5 (0.3) 2 (0.1) 1 (0.1) C. tropicalis (1,253) S 1,223 (97.6) 0 (0.0) 0 (0.0) SDD 5 (0.4) 2 (0.2) 2 (0.2) R 2 (0.2) 1 (0.1) 16 (1.3) C. krusei (312) S 9 (2.8) 0 (0.0) 0 (0.0) SDD 177 (56.7) 0 (0.0) 0 (0.0) R 124 (39.7) 1 (0.4) 1 (0.4) C. lusitaniae (134) S 130 (97.0) 0 (0.0) 0 (0.0) SDD 2 (1.4) 1 (0.8) 0 (0.0) R 1 (0.8) 0 (0.0) 0 (0.0) C. dubliniensis (103) S 94 (91.3) 0 (0.0) 0 (0.0) SDD 6 (5.8) 0 (0.0) 0 (0.0) R 1 (1.0) 0 (0.0) 2 (1.9) C. guilliermondii (92) S 83 (90.2) 0 (0.0) 0 (0.0) SDD 6 (6.5) 0 (0.0) 0 (0.0) R 0 (0.0) 2 (2.2) 1 (1.1) C. pellliculosa (34) S 34 (100) 0 (0.0) 0 (0.0) SDD 0 (0.0) 0 (0.0) 0 (0.0) C. kefyr (33) S 33 (100) 0 (0.0) 0 (0.0) SDD 0 (0.0) 0 (0.0) 0 (0.0) C. famata (19) S 14 (73.7) 0 (0.0) 0 (0.0) SDD 5 (26.3) 0 (0.0) 0 (0.0) C. rugosa (19) S 19 (100) 0 (0.0) 0 (0.0) SDD 0 (0.0) 0 (0.0) 0 (0.0) a S, MIC of 8 g/ml; SDD, MIC of 16 to 32 g/ml; R, MIC of 64 g/ml. b Voriconazole susceptibility categories are as described by Pfaller et al. (30). creased potencies of both fluconazole and voriconazole were observed among C. glabrata (modal MICs of 8 g/ml and 0.12 to 0.25 g/ml, respectively) and C. krusei (modal MICs of 32 g/ml and 0.25 g/ml, respectively), although 99% of C. krusei isolates were susceptible to voriconazole at the 1- g/ml breakpoint. The extent of cross-resistance between fluconazole and voriconazole may be seen more clearly in Table 2 and Fig. 1. All Candida 13, All Candida minus 13, (97.7) 0.0 (0.1) 0.5 (1.4) 5.9 (0.8) C. krusei C. albicans 7, C. glabrata 1, (93.9) 0.0 (0.1) 1.5 (1.5) 32.4 (4.5) C. parapsilosis 1, C. tropicalis 1, C. krusei C. lusitaniae C. dubliniensis C. guilliermondii C. pelliculosa C. kefyr C. famata (100) (0.0) C. rugosa a Values in parentheses are categorical agreement and error rates obtained using the following categories for fluconazole: susceptible, MIC of 32 g/ml (S and SDD combined); resistant, MIC of 64 g/ml. Although the MICs for voriconazole were at least 16- to 32- fold lower than the corresponding fluconazole MICs for each isolate tested, there was a strong positive correlation (r 0.93) between voriconazole and fluconazole MICs (Fig. 1). All of the fluconazole-susceptible isolates were susceptible to voriconazole, as were 97.8% of the fluconazole-sdd isolates (Table 2). Among 396 fluconazole-resistant isolates, 192 (48%) were susceptible, 94 (24%) were SDD, and 110 (28%) were resistant to voriconazole. The CLSI does not recommend that laboratories test C. krusei against fluconazole, given its poor clinical response to this agent and the fact that the intrinsic resistance manifested by this species may be underrepresented by the in vitro results (5, 15, 26, 29, 31, 32). In contrast, voriconazole appears quite active against C. krusei (310 of 312 isolates [99%] were susceptible at an MIC of 1 g/ml [Table 2]), and the clinical activity looks promising as well (5, 12, 19, 22). When the C. krusei results are eliminated from the total, we again find that 100% of fluconazole-susceptible isolates and 97% of fluconazole-sdd isolates are susceptible to voriconazole but that only 25% of fluconazole-resistant isolates are susceptible to voriconazole (Table 2). Alternatively, if one considers all isolates identified as C. krusei to be resistant to fluconazole, then 378 of 582 fluconazole-resistant isolates (65%) would be susceptible to voriconazole (data not shown). When the fluconazole test result category (S, SDD, or R) was used to predict the voriconazole category, the absolute categorical agreement between the test results was 91.6%, with no VME (false-susceptible error), 1.4% ME (false-resistant error), and a 7.0% minor error rate (Table 3). Given the fact that the fluconazole results clearly do not predict the susceptibility of C. krusei to voriconazole (Tables 1 and 2), we have also factored the C. krusei results out of the analysis, with a resulting improvement in categorical agreement (93.6%) and a decrease in both ME (0.5%) and minor errors (5.9%) (Table 3). The absolute categorical agreements for 12 individual species of Candida are shown in Table 3. A categorical agreement
5 74 PFALLER ET AL. J. CLIN. MICROBIOL. of 91% or better (range, 91.3 to 100%) was observed for all species except C. glabrata, C. famata, and C. krusei. As seen with C. krusei, the fluconazole results also underestimated the activity of voriconazole against C. glabrata and C. famata (Tables 2 and 3). All fluconazole-susceptible isolates of these two species were also susceptible to voriconazole (Table 2). Likewise, 98% of C. glabrata isolates and all five C. famata isolates that were SDD to fluconazole were susceptible to voriconazole. In contrast, only 16.5% of fluconazole-resistant isolates of C. glabrata were susceptible to voriconazole, and 40% were resistant. Importantly, 72 of 73 voriconazole-resistant isolates (98.6%) were also resistant to fluconazole. Clearly, it is most important to detect those isolates of C. glabrata that may be resistant to voriconazole, and in that regard fluconazole performs quite well as a surrogate marker; there were no false-susceptible results (VME) and only 1.5% false-resistant results (ME). Given that 98% of C. glabrata isolates that were SDD to fluconazole were susceptible to voriconazole, one may improve the ability of the fluconazole MIC test to predict susceptibility of C. glabrata to voriconazole by combining the fluconazole S and SDD categories and using fluconazole MICs of 32 g/ml to identify voriconazole-susceptible isolates and MICs of 64 g/ml to identify voriconazole resistance. Using this criterion, the categorical agreement for C. glabrata improves to 93.9%, with 0.1% VME, 1.5% ME, and 4.5% minor errors (Table 3). Similarly, the categorical agreement for C. famata improves from 73.7% to 100%. Applying this modified criterion to the entire collection of isolates (minus C. krusei) results in an overall categorical agreement of 97.7%, with 0.1% VME and 1.4% ME (Table 3). Previously, we conducted a similar analysis using fluconazole results to predict the susceptibility of Candida spp. to ravuconazole as a proof of concept regarding the use of surrogate markers or class representatives in antifungal susceptibility testing (29). This strategy has been used for decades in antibacterial susceptibility testing to develop practical alternatives for the microbiology laboratory when specific diagnostic susceptibility testing reagents are limited or unavailable (11, 14, 16 18). Given the lack of FDA-approved testing systems for voriconazole, the approach described in the present study provides a useful strategy for laboratories in the effort to optimize antifungal therapy of candidal infections. In addition to providing a strategy to predict voriconazole susceptibility and resistance among Candida spp., these results provide strong support for the concerns of several investigators regarding the issue of cross-resistance between fluconazole and voriconazole (1, 8, 13, 20). By using an extensive global collection of clinically important isolates encompassing more than 12 species, we validate concerns originating from single-center experiences and rightly focus attention on C. glabrata as the species most likely to demonstrate cross-resistance among the azoles. Fluconazole functioned well as a surrogate marker for voriconazole susceptibility when applied to this collection of clinically significant isolates of Candida spp. The absolute categorical agreement of 91.6% (93.6% without C. krusei), with no VME among more than 13,000 isolates tested, easily meets the recognized criteria for a reliable surrogate marker as applied to antibacterial susceptibility testing (4, 11, 14, 16 18). Given the greater potency of voriconazole over fluconazole, the use of fluconazole as a surrogate marker for voriconazole susceptibility was clearly improved by designating those isolates with fluconazole MICs of 32 g/ml (S and SDD categories combined) as being susceptible to voriconazole, with the resistant category staying the same at 64 g/ml. The resulting 97.7% categorical agreement and 0.1% VME rate is excellent for a surrogate marker test. In conclusion, we have demonstrated the existence of crossresistance between fluconazole and voriconazole, with the greatest emphasis on C. glabrata. Furthermore, we have shown that the availability of voriconazole susceptibility testing results for Candida spp., in any medical center currently performing antifungal susceptibility testing of fluconazole, can be accomplished by using the fluconazole result as a surrogate marker for voriconazole susceptibility and resistance. Specifically, fluconazole MICs of 32 g/ml predict susceptibility and MICs of 64 g/ml predict resistance to voriconazole. The occurrence of false-susceptible and false-resistant errors with this expanded application of the class representative concept to selected triazoles was very low and was acceptable for surrogate marker testing. By using a predictor agent with a generally narrower spectrum of activity or reduced potency, such as fluconazole, a conservative and safe categorical estimation of activity can be made until specific voriconazole-containing FDA-approved products are available. As commercial voriconazole susceptibility products become available, they should rapidly replace the interim use of this surrogate marker for clinical testing. ACKNOWLEDGMENTS This study was supported in part by unrestricted research grants from Pfizer Inc. Linda Elliott provided excellent support in the preparation of the manuscript. We appreciate contributions of all participants in the Global Antifungal Surveillance Program. For a complete listing of participants, please go to /path_folder/research/acknowledgments/artemis_participants.pdf. REFERENCES 1. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantion 80: Andes, D In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47: Espinel-Ingroff, A., M. Pfaller, S. A. Messer, C. C. Knapp, S. Killian, H. A. Norris, and M. A. Ghannoum Multicenter comparison of the Sensititre Yeast One Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J. Clin. Microbiol. 37: Ferraro, M. J., and J. H. Jorgensen Instrument-based antibacterial susceptibility testing, p In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, DC. 5. Fukuoka, T., D. A. Johnston, C. A. Winslow, M. J. de Groot, C. Burt, C. A. Hitchocok, and S. G. Filler Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob. Agents Chemother. 47: Graybill, J. R Voriconazole for candidosis: an important addition? Lancet 366: Hazen, K. C., and S. A. Howell Candida, Cryptococcus, and other yeasts of medical importance, p In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. American Society for Microbiology, Washington, DC. 8. Imhof, A., A. Balajee, D. N. Fredricks, J. A. Englund, and K. A. Marr Breakthrough fungal infections in stem cell transplant patients receiving voriconazole. Clin. Infect. Dis. 39: Johnson, L. B., and C. A. Kauffman Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36:
6 VOL. 45, 2007 SUSCEPTIBILITY TESTING OF VORICONAZOLE Joly, S., C. Pujol, M. Rysz, K. Vargas, and D. R. Soll Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis. J. Clin. Microbiol. 37: Jones, R. N., and M. A. Pfaller, and the SENTRY Antimicrobial Surveillance Program Participants Group (USA) Can. antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from the SENTRY Antimicrobial Surveillance Program ( ). Diagn. Microbiol. Infect. Dis. 39: Kullberg, B. J., J. D. Sobel, M. Ruhnke, P. G. Pappas, C. Viscoli, J. H. Rex, J. D. Cleary, E. Rubinstein, L. W. R. Church, J. M. Brown, H. T. Schlammn, I. T. Oberska, F. Hilton, and M. R. Hodges Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 366: Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44: National Committee for Clinical Laboratory Standards Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 2nd ed., M23 A2. National Committee for Clinical Laboratory Standards, Wayne, PA. 15. National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed., M27 A2. National Committee for Clinical Laboratory Standards, Wayne, PA. 16. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial disk susceptibility tests; approved standard, 8th ed., M2 A8. National Committee for Clinical Laboratory Standards, Wayne, PA. 17. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed., M7 A6. National Committee for Clinical Laboratory Standards, Wayne, PA. 18. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing; 13th informational supplement, M100 S13. National Committee for Clinical Laboratory Standards, Wayne, PA. 19. Ostrosky-Zeichner, L., A. M. L. Oude Lashof, B. J. Kullberg, and J. H. Rex Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22: Panackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44: Pearson, M. M., P. D. Rogers, J. D. Cleary, and S. W. Chapman Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 37: Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lustar, A. Espinel- Ingroff, and E. Johnson Voriconazole treatment for less-common, emerging or refractory fungal infections. Clin. Infect. Dis. 36: Pfaller, M. A., and D. J. Diekema Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40: Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, H. Huynh, and R. J. Hollis Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole. J. Clin. Microbiol. 40: Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46: Pfaller, M. A., and D. J. Diekema Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl. 1): Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis Activities of fluconazole and voriconazole against 1,526 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, J. Clin. Microbiol. 41: Pfaller, M. A., D. J. Diekema, L. Boyken, S. A. Messer, S. Tendolkar, and R. J. Hollis Evaluation of Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J. Clin. Microbiol. 41: Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42: Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44: Pfaller, M. A., D. J. Diekema, and D. J. Sheehan Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19: Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, M. G. Rinaldi, T. J. Walsh, and A. L. Barry Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infection. Clin. Infect. Dis. 24: Rex, J. H., and M. A. Pfaller Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:
Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationReceived 29 October 2009/Returned for modification 4 January 2010/Accepted 9 February 2010
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2010, p. 1366 1377 Vol. 48, No. 4 0095-1137/10/$12.00 doi:10.1128/jcm.02117-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Results from
More informationTriazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2006, p. 529 535 Vol. 44, No. 2 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.2.529 535.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Triazole
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationon December 9, 2018 by guest
JCM Accepts, published online ahead of print on 27 June 2012 J. Clin. Microbiol. doi:10.1128/jcm.00937-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Progress in Antifungal
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationon November 3, 2018 by guest
JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1811 1820 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00134-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationRapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2010, p. 2205 2212 Vol. 48, No. 6 0095-1137/10/$12.00 doi:10.1128/jcm.02321-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Rapid Antifungal
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationAntifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study
Antifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study G Marshall Lyon III, Emory University Sulaiman Karatela, Emory University Susan Sunay, Emory University Yaffa Adiri,
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationAvailable online at journal homepage:
Kaohsiung Journal of Medical Sciences (2012) 28, 306e315 Available online at www.sciencedirect.com journal homepage: http://www.kjms-online.com ORIGINAL ARTICLE Fluconazole exposure rather than clonal
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationSpecies distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002
Fluconazole J Microbiol Immunol susceptibility Infect of Candida 2004;37:236-241 Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002 Jiun-Ling Wang
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Therapeutics Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Impact of the New Clinical Breaking Points Proposed
More informationReceived 5 August 2004/Accepted 26 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 512 517 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.512 517.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationReceived 12 May 2010/Returned for modification 24 June 2010/Accepted 6 July 2010
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2010, p. 3153 3157 Vol. 48, No. 9 0095-1137/10/$12.00 doi:10.1128/jcm.00952-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More informationJCM Accepts, published online ahead of print on 3 February 2010 J. Clin. Microbiol. doi: /jcm
JCM Accepts, published online ahead of print on 3 February 2010 J. Clin. Microbiol. doi:10.1128/jcm.02363-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationIn Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2008, p. 150 156 Vol. 46, No. 1 0095-1137/08/$08.00 0 doi:10.1128/jcm.01901-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro Susceptibility
More informationFluconazole Susceptibility Profile of Candida isolates Recovered from Patients Specimens Admitted to Yazd Central Laboratory
Iranian Journal of Pharmaceutical Research (2008), 7 (1): 69-75 Received: June 2007 Accepted: November 2007 Copyright 2008 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationThe Evolving Role of Antifungal Susceptibility Testing. Gregory A. Eschenauer and Peggy L. Carver
S PECIAL A RTICLE The Evolving Role of Antifungal Susceptibility Testing Gregory A. Eschenauer and Peggy L. Carver Although increasing numbers of hospital microbiology laboratories are performing antifungal
More informationRapid Species Identification and Antifungal Susceptibility Testing of Candida Isolated from Different Hospital Acquired Infections by VITEK 2 System
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 764-772 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.090
More informationAntifungal susceptibility testing using the E test: comparison with the broth macrodilution technique
Journal of Antimicrobial Chemotherapy (996) 7, 65-7 Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique Sharon C. A. Chen, Maryann L. O'Donnell, Suzannah
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationMultilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1543 1548 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01510-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multilaboratory
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationReceived 25 March 2008/Returned for modification 12 May 2008/Accepted 15 June 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2008, p. 2620 2629 Vol. 46, No. 8 0095-1137/08/$08.00 0 doi:10.1128/jcm.00566-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Correlation
More informationAntifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units
Journal of Medical Microbiology (2012), 61, 389 393 DOI 10.1099/jmm.0.037895-0 Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian
More informationACCEPTED JCM REVISED. In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and
JCM Accepts, published online ahead of print on 1 November 00 J. Clin. Microbiol. doi:./jcm.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationResearch Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method
The Scientific World Journal Volume 2013, Article ID 236903, 6 pages http://dx.doi.org/10.1155/2013/236903 Research Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationReceived 7 March 2002/Returned for modification 16 April 2002/Accepted 13 June 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2002, p. 3204 3208 Vol. 40, No. 9 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.9.3204 3208.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More informationCandidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex
Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex ORIGINAL ARTICLE ABSTRACT Introduction: Although the spectrum of fungi causing bloodstream fungal infections
More informationdida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans
dida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans Key words: Susceptibility test, IC99, miconazole, fluconazole, itraconazole, Micro-dilution method, 96-multiwell plate Table 1. Cunteffis
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationAAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 1 March 0 Antimicrob. Agents Chemother. doi:./aac.010- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationSafety and Tolerability of Voriconazole in Patients with Baseline Renal Insufficiency
AAC Accepts, published online ahead of print on 26 March 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05841-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Safety and
More informationSYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II
SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II DURAN NIZAMI 1, MUZ MUSTAFA 2, DURAN GULAY GULBOL 3, OZER BURCIN 1, ONLEN YUSUF 4 1 Mustafa
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationEpidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients
OPEN (2017) 6, e87; doi:10.1038/emi.2017.74 www.nature.com/emi ORIGINAL ARTICLE Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients Ping-Feng
More informationIN-VITRO SENSITIVITY OF AMPHOTERICIN B, ITRACONAZOLE AND FLUCONAZOLE - RESISTANT AGAINST CANDIDA ALBICANS
IJPSR (2011), Vol. 2, Issue 11 (Research Article) Received on 03 July, 2011; received in revised form 17 September, 2011; accepted 29 October, 2011 IN-VITRO SENSITIVITY OF AMPHOTERICIN B, ITRACONAZOLE
More informationDepartment of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran 3
Curr Med Mycol, 2016 Jun, 2(2): 34-39 Article Original In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran Shokohi T 1,2, Badali H 1,2, Amirrajab N 3, Ataollahi MR
More informationAntifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients
ISSN: 2319-7706 Volume 4 Number 3 (2015) pp. 716-720 http://www.ijcmas.com Original Research Article Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients Deepak Kumar 1, Sayan
More informationUse of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species
Brazilian Journal of Microbiology 44, 4, 1257-1266 (2013) ISSN 1678-4405 Copyright 2013, Sociedade Brasileira de Microbiologia www.sbmicrobiologia.org.br Research Paper Use of the VITEK 2 system to identify
More informationReceived 12 May 2009/Returned for modification 22 June 2009/Accepted 12 August 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2009, p. 3170 3177 Vol. 47, No. 10 0095-1137/09/$08.00 0 doi:10.1128/jcm.00942-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. In Vitro
More informationCandida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains
Medical Mycology March 2009, 47, 137143 Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains MARÍA MERCEDES PANIZO, VERA REVIÁKINA,
More informationon March 29, 2019 by guest
JCM Accepts, published online ahead of print on 4 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationEchinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical
JCM Accepts, published online ahead of print on 29 May 2013 J. Clin. Microbiol. doi:10.1128/jcm.00308-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 JCM00308-13 REVISION
More informationPotato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1455 1461 Vol. 46, No. 5 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.5.1455 1461.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationDepartment of Pathology, University of Iowa College of Medicine, Iowa City, 1 and The JONES Group/JMI Laboratories, North Liberty, 2 Iowa
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2002, p. 1032 1037 Vol. 46, No. 4 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.4.1032 1037.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
Journal of Antimicrobial Chemotherapy (2008) 62, 1094 1100 doi:10.1093/jac/dkn304 Advance Access publication 25 July 2008 Evaluation of aminocandin and caspofungin against Candida glabrata including isolates
More informationCandidemia: New Sentinel Surveillance in the 7-County Metro
Candidemia: New Sentinel Surveillance in the 7-County Metro Brittany VonBank, MPH Paula Vagnone, MT (ASCP) 651-201-5414 www.health.state.mn.us Health Care-associated Infections & Antimicrobial Resistance
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationReceived 6 May 2008; returned 15 June 2008; revised 7 August 2008; accepted 11 August 2008
Journal of Antimicrobial Chemotherapy (2008) 62, 1379 1385 doi:10.1093/jac/dkn381 Advance Access publication 8 September 2008 Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole
More informationYeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With Neutropenia
Jundishapur J Microbiol. 2014 September ; 7(9): e11858. Published online 2014 September 1. DOI: 10.5812/jjm.11858 Research Article Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients
More informationSystemic Candidiasis for the clinicians: between guidelines and daily clinical practice
Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice Anastasia Antoniadou Assoc. Professor Internal Medicine and Infectious Diseases National and Kapodistrian University
More informationEmerging Fungal Diseases
INVITED ARTICLE EMERGING INFECTIONS Larry J. Strausbaugh, Section Editor Emerging Fungal Diseases Marcio Nucci 1 and Kieren A. Marr 2,3 1 University Hospital, Universidade Federal do Rio de Janeiro, Rio
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationIdentification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey
DOI 10.1186/s12941-016-0153-1 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Identification and antifungal susceptibility of Candida species isolated from bloodstream infections
More informationEpidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review
Epidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review Haydar A a a Department of Internal Medicine, Kulliyyah of Medicine,
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01268.x Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital R. Luzzati 1,2, B. Allegranzi 1, L. Antozzi 1, L.
More informationInternational Journal of Molecular and Clinical Microbiology
International Journal of Molecular and Clinical Microbiology 2 (2012) 211-217 International Journal of Molecular and Clinical Microbiology In vitro antifungal activity of Clotrimazole, Miconazole and Ketoconazol
More informationArticles. Vol 366 October 22,
versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial B J Kullberg, J D Sobel, M Ruhnke, P G Pappas, C Viscoli, J H
More informationReceived 1 December 2009/Accepted 26 January 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2010, p. 1541 1546 Vol. 54, No. 4 0066-4804/10/$12.00 doi:10.1128/aac.01688-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Evaluation
More informationCandida glabrata: an emerging pathogen in Brazilian tertiary care hospitals
Medical Mycology January 2013, 51, 38 44 Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals ARNALDO L. COLOMBO *, MARCIA GARNICA, LUIS FERNANDO ARANHA CAMARGO, CLOVIS ARNS DA CUNHA,
More informationAntifungal drug resistance among Candida species: mechanisms and clinical impact
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Supplement article Antifungal drug resistance among Candida species: mechanisms and clinical impact Maurizio Sanguinetti, 1 Brunella Posteraro
More information